Ankara Bilkent Şehir Hastanesi ( Site 2100)

Ankara 06800

1 studies enrolling now · 1 studies all time

What they study most

Non-small Cell Lung Cancer

Studies at this site

• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) — Recruiting now